Trial Profile
An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
- Indications Age-related macular degeneration
- Focus Adverse reactions
- 20 Sep 2018 Status changed from active, no longer recruiting to completed.
- 02 Nov 2015 New trial record